Ten patients (one man and nine women, mean age 48.8 +/- 20.1) presented with a stereotypical and undescribed type of head pain. They complained of strictly unilateral, shooting pain paroxysms starting in a focal area of the posterior parietal or temporal region and rapidly spreading forward to the ipsilateral eye (n = 7) or nose (n = 3) along a lineal or zigzag trajectory, the complete sequence lasting 1-10 s. Two patients had ipsilateral lacrimation, and one had rhinorrhoea at the end of the attacks. The attacks could be either spontaneous or triggered by touch on the stemming area (n = 2), which could otherwise remain tender or slightly painful between the paroxysms (n = 5). The frequency ranged from two attacks per month to countless attacks per day, and the temporal pattern was either remitting (n = 5) or chronic (n = 5). This clinical picture might be a variant of an established headache or represent a novel syndrome.
Carbamazepine is a widely used drug associated with numerous side effects including skin eruptions that appear in about 4% of patients. Epicutaneous tests have been used with variable success in skin drug reactions. The purpose of this study was to work out the efficacy of this type of test in carbamazepine reactions. Five patients with carbamazepine cutaneous reaction were studied. Clinical, laboratory and histopathological data were recorded. The 5 patients and 20 controls were tested with carbamazepine 1% in petrolatum. In 4 patients the carbamazepine epicutaneous test was positive. The 20 healthy controls were negative. Epicutaneous testing is a simple and helpful method in detecting carbamazepine hypersensitivity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.